GlassScriptPhysician profile
Bridgette Chenevert Marcotte
NPI 1578964714
$3,858.18
in general payments reported to CMS, 2019-2025
22 companies · $836 in 2025
The $836 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $582 · 2022: $777 · 2023: $658 · 2024: $1,005 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.58 | 2021-2025 | |
| Novo Nordisk INC | $365.86 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $328.27 | 2021-2024 | Trintellix, Vpriv |
| Kyowa Kirin, INC. | $191.72 | 2023-2025 | Crysvita |
| Pfizer INC. | $190.38 | 2021-2023 | |
| Amgen INC. | $172.69 | 2021-2025 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $154.64 | 2021-2025 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $139.34 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $125.65 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $101.90 | 2024-2025 | Rexulti |
| Abbott Laboratories | $92.76 | 2021-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $68.51 | 2022-2025 | Gvoke Hypopen |
| Arbor Pharmaceuticals, INC. | $51.36 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.69 | 2025 | Caplyta |
| Exact Sciences Corporation | $46.37 | 2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $44.53 | 2021-2022 | |
| Sanofi Pasteur INC. | $30.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $26.45 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.70 | 2022 | |
| Currax Pharmaceuticals LLC | $15.46 | 2024 | Contrave |
| Sobi, INC | $14.21 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Marcotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.